Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, Inc. (NASDAQ: NTRA) announced the publication of the groundbreaking SMART study in the American Journal of Obstetrics and Gynecology, demonstrating the efficacy of its non-invasive prenatal testing (NIPT) for detecting 22q11.2 deletion syndrome (22q11.2DS). Enrolling over 20,000 patients globally, the study reveals a prevalence of 1 in 1,524 pregnancies, with Panorama detecting all common cases and achieving a low false positive rate of 0.05%. This supports the expansion of routine prenatal screening to include 22q11.2DS, emphasizing the need for diagnostic follow-ups.
Natera, Inc. (NASDAQ: NTRA) announced new data presentations at the ASCO GI Symposium from January 20-22, 2022, concerning its tumor-informed molecular residual disease test, Signatera. Highlighted studies include two oral presentations and four posters focusing on colorectal, pancreatic, and anal cancers. One study shows how MRD testing can predict treatment benefits for colorectal cancer patients post-surgery. An investor call reviewing the ASCO GI results is scheduled for January 24, 2022, at 1:30 PM PT.
Natera, Inc. (NASDAQ: NTRA) has announced the appointment of Dr. Alexey Aleshin as General Manager of Early Cancer Detection (ECD), part of its strategic expansion into the ECD market. Dr. Aleshin, who has extensive experience in oncology, will continue overseeing medical affairs while leading ECD initiatives. The company aims to leverage a biobank of colorectal cancer samples from Aarhus University, potentially accelerating ECD product development and FDA approval. CEO Steve Chapman emphasizes the opportunity to improve early cancer detection, enhancing patient outcomes.
Austin, Texas-based Natera, a leader in personalized genetic testing, announced a live presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. PT. CEO Steve Chapman and CFO Mike Brophy will discuss recent business activities and Natera's growth plans in the genetic testing industry. The presentation will address its impact on critical health decisions. Interested parties can access the live webcast and the archived presentation on investor.natera.com.
Natera, Inc. (NASDAQ: NTRA) presented key findings at the 2021 San Antonio Breast Cancer Symposium highlighting the use of its Signatera test in high-risk breast cancer patients. The studies indicated that detecting circulating tumor DNA (ctDNA) both pre- and post-surgery was crucial in predicting disease relapse, with ctDNA status being the strongest predictor of patient outcomes. As a custom-built test for monitoring cancer treatment, Signatera has shown significant potential in clinical settings for improving patient care and optimizing treatment strategies.
Natera, Inc. (NASDAQ: NTRA) announced the acceptance of the first manuscript from its groundbreaking SMART study for publication in the American Journal of Obstetrics and Gynecology. This study validates the Panorama non-invasive prenatal test (NIPT) for common trisomies, confirming its 99% sensitivity and >99.5% specificity for trisomy 21. The SMART study, involving over 20,000 patients, utilized an advanced AI algorithm, Panorama AI, which lowered the no-call rate to 1.5%. This research enhances the confidence of physicians in screening for genetic disorders during pregnancy.
Natera announced that the CMS has issued a final local coverage determination for pan-cancer immunotherapy monitoring using its Signatera molecular residual disease test. This coverage applies to Medicare patients undergoing immunotherapy, significantly expanding access to personalized monitoring. The Signatera test has shown high predictive accuracy in identifying non-responders early in treatment, aiming to improve cancer care outcomes. Natera sees this development as a crucial step in enhancing treatment decisions across various tumor types.
Natera, Inc. (NASDAQ: NTRA) reported a strong third quarter for 2021, achieving $158.1 million in total revenues, a 61.1% increase year-over-year. Product revenues rose to $150.7 million, driven by a 55.4% increase in processed tests, totaling 407,300. Despite a net loss of $151.3 million or ($1.63) per diluted share, the company raised its 2021 revenue guidance to $615-$625 million. Significant advancements include an exclusive biobank license and positive results from the Trifecta Study in kidney transplant.
Natera, Inc. (NASDAQ: NTRA) announced initial results from the Trifecta study, the largest biopsy-matched evaluation of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients. The study analyzed over 300 biopsy-matched samples, revealing that the Prospera test with quantification demonstrated an AUC of 0.81 for rejection detection, improving to 0.91 when differentiating rejection from quiescence. Natera anticipates publishing comprehensive results in early 2022, reinforcing its leadership in cfDNA technology.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
